上海凯利泰医疗科技股份有限公司 详式权益变动报告书 | 上市公司 | 上海凯利泰医疗科技股份有限公司 | | --- | --- | | 上市地点 | 深圳证券交易所 | | 股票简称 | ST 凯利 | | 股票代码 | 300326 | 信息披露义务人： | 序号 | 名称/姓名 | 住所 | | | | | | 通讯地址 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 上海欣诚意投资 | 上海市青浦区五厍浜路 | | | | 201 | 号 5 幢 | | | | | | 有限公司 | 一层 A | 区 | 101 | 室 | | | 上海市青浦区天辰路 | | 508 | | 2 | 袁征 | 上海市浦东新区 | | | | | | 号 1 室 | 号楼 | 301 | | 3 | 上海仲翼投资有 | 上海市青浦区五厍浜路 | | | | 201 | 号 5 幢 | | | | | | 限公司 | 一层 B | 区 | 101 | 室 | | | | | | 一致行动人： | 序号 | 名称 ...

证券代码：300326 证券简称：ST 凯利 公告编号：2025-065 上海凯利泰医疗科技股份有限公司 关于持股 5%以上股东增持公司股份计划进展 暨股份变动触及 1%公告 公司持股5%以上的股东上海欣诚意投资有限公司、袁征先生、上海仲翼投资有限公司保 证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1 中竞价交易方式累计增持公司股份5,178,910股，占公司总股本的0.7223%，增持 金额合计为人民币39,181,670.30元。具体详见公司于2025年4月23日披露的《关 于持股5%以上股东增持公司股份计划期限过半的进展公告》（公告编号：2025-012） 截至2025年7月11日，欣诚意和袁征先生以集中竞价交易方式累计增持公司 股 份 8,756,910 股，占公司总股本的 1.2213% ，增持金额合计为人民币 58,240,583.30元。此外，欣诚意和袁征先生一致行动人上海仲翼投资有限公司 （袁征先生的兄弟严航先生持股100%并任执行董事兼总经理，以下简称"仲翼投 资"）于2025年5月8日至5月9日期间，以集中竞价交易方式增持公司股票 1,000,000股， ...

Group 1 - Aishuo Co., Ltd. expects a net loss of 170 million to 280 million yuan for the first half of 2025, with a net loss of 410 million to 520 million yuan after excluding non-recurring gains and losses [1] - Changcheng Military Industry anticipates a net loss of 25 million to 29.5 million yuan for the first half of 2025, with a net loss of 35 million to 41 million yuan after excluding non-recurring gains and losses [1] - Changyuan Donggu expects a net profit of 155 million to 180 million yuan for the first half of 2025, representing a year-on-year increase of 62.65% to 88.88% [1] Group 2 - Beifang Navigation forecasts a net profit of 105 million to 120 million yuan for the first half of 2025, turning around from a loss of 74.2168 million yuan in the same period last year [3] - Xizi Clean Energy expects a net profit of 130 million to 180 million yuan for the first half of 2025, a decrease of 47.40% to 62.01% compared to the same period last year [4] - Tianbao Infrastructure anticipates a net profit of 90 million to 130 million yuan for the first half of 2025, representing a year-on-year increase of 1581.80% to 2329.27% [4] Group 3 - Taiping Bird expects a net profit of approximately 77.7 million yuan for the first half of 2025, a decrease of about 55% compared to the same period last year [6] - Xibu Chuangye forecasts a net profit of approximately 295 million yuan for the first half of 2025, an increase of 88.99% compared to the same period last year [8] - Zhengbang Technology expects a net profit of 190 million to 210 million yuan for the first half of 2025, a year-on-year increase of 249.03% to 264.72% [9] Group 4 - Songzhi Co., Ltd. anticipates a net profit of 140 million to 170 million yuan for the first half of 2025, representing a year-on-year increase of 53.58% to 86.49% [10] - Hailide expects a net profit of 280 million to 310 million yuan for the first half of 2025, a year-on-year increase of 47.65% to 63.47% [12] - Chenhua Co., Ltd. forecasts a net profit of 48.8176 million to 56.6284 million yuan for the first half of 2025, a year-on-year increase of 25% to 45% [13] Group 5 - Yuanlin Co., Ltd. expects a net loss of 68 million to 92 million yuan for the first half of 2025, with a net loss of 70 million to 95 million yuan after excluding non-recurring gains and losses [14] - Chuanhua Zhili anticipates a net profit of 500 million to 550 million yuan for the first half of 2025, representing a year-on-year increase of 72.78% to 90.06% [15] - Longyuan Technology expects a net profit of 26 million to 31 million yuan for the first half of 2025, a year-on-year increase of 116.61% to 158.26% [17] Group 6 - Jiangshan Co., Ltd. forecasts a net profit of 300 million to 360 million yuan for the first half of 2025, a year-on-year increase of 75.65% to 110.78% [32] - Ganli Pharmaceutical expects a net profit of 600 million to 640 million yuan for the first half of 2025, a year-on-year increase of 100.73% to 114.12% [33] - Zhongyan Chemical's subsidiary signed a 6.809 billion yuan mining rights transfer contract [35]

Core Viewpoint - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors regarding operational updates, stock performance, and significant corporate actions. Group 1: Company Announcements - Huaguang Huaneng's stock has experienced five consecutive trading limit increases, with a trading volume of 29.41% over the last five days, indicating potential irrational speculation, although the company's fundamentals remain stable [3]. - Andeli's actual controller Wang An transferred 90% of the shares of BVI Ping An to his daughter Wang Meng, but this transfer does not affect the company's governance structure or control [5]. - Singshan Co. received a court notice regarding the judicial disposal of 4.26 million shares, accounting for 0.19% of the total share capital, but this is not expected to impact daily operations [6]. - Three Gorges Energy reported a total power generation of 39.314 billion kWh in the first half of 2025, an increase of 8.85% year-on-year [7]. - New Zhonggang's stock has seen four consecutive trading limits, with no significant media reports or market rumors affecting its price [8]. - ST Yazhen's stock was suspended for one trading day due to a tender offer by its controlling shareholder, with a total of 55.1779 million shares involved [9]. - Zhongli Co. plans to invest 478 million yuan in a smart logistics equipment project [11]. - Zhuoran Co. approved the sale of 95% equity in a subsidiary for 723 million yuan, which does not constitute a related party transaction [12]. - Jerry Co. received a project award for a natural gas booster station worth approximately 850 million USD [13]. - Qujiang Cultural Tourism plans to publicly transfer 38% equity in a subsidiary valued at approximately 22.98 million yuan [14]. - Foshan Technology intends to publicly transfer 100% equity of a subsidiary with a starting price of 180 million yuan [15]. Group 2: Performance Forecasts - Xianda Co. expects a net profit increase of 2443.43% to 2834.73% in the first half of 2025, driven by rising product prices and improved cost control [25]. - Muyuan Co. anticipates a net profit of 10.5 billion to 11 billion yuan, reflecting a year-on-year growth of 924.6% to 973.39% due to increased pig sales and lower costs [26]. - Jiangshan Co. forecasts a net profit increase of 75.65% to 110.78% in the first half of 2025, supported by product optimization and cost control [28]. - Chenguang Bio's net profit is expected to rise by 102.33% to 132.38%, primarily due to improved market conditions for its cottonseed business [29]. - Xinlian Electronics predicts a net profit of 166 million to 198 million yuan, marking a turnaround from a loss in the previous year [30]. - Wohua Pharmaceutical expects a net profit increase of 233.89% to 378.27% due to market adaptation and cost control measures [31]. - Yonghe Co. anticipates a net profit increase of 126.30% to 148.49% driven by rising refrigerant prices [32]. - Shanghai Pharmaceuticals expects a net profit increase of approximately 52% due to the acquisition of a stake in a subsidiary [34]. - AVIC Heavy Machinery forecasts a net profit decline of about 33.29% due to falling product prices [35]. - Jingneng Real Estate expects a net loss of 190 million to 210 million yuan in the first half of 2025 due to reduced scale and increased expenses [36]. Group 3: Major Contracts - Fengfan Co. won a bid for a project worth approximately 337 million yuan from the Southern Power Grid [37]. - Longjian Co. was part of a consortium that won a project bid worth 362 million yuan for infrastructure construction [38].

Core Viewpoint - ST凯利's major shareholders plan to increase their stake in the company by acquiring at least 14.339 million shares over a six-month period starting from July 11, 2025 [1] Group 1: Shareholder Actions - The shareholders involved include Shanghai Kaicheng Juntai Investment Co., Ltd., Ms. Li Hong, Mr. Liu Shuangquan, and Ms. Wei Yongmei [1] - The total shares held by the increasing stakeholders amount to 5.00% of the company [1] - The funding for the share purchase will be sourced from their own or self-raised funds [1] Group 2: Potential Risks - The implementation of the share purchase plan may be delayed or not executed due to changes in the securities market, policy factors, or if the required funds are not available in time [1]

证券代码：300326 证券简称：ST 凯利 公告编号：2025-064 上海凯利泰医疗科技股份有限公司 关于持股 5%以上股东增持公司股份计划的公告 公司合计持股5%以上的股东及其一致行动人上海凯诚君泰投资有限公司、李虹女士、刘 双全先生、魏永梅女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、上海凯利泰医疗科技股份有限公司（以下简称"公司"）合计持股5%以 上股东上海凯诚君泰投资有限公司（以下简称"凯诚君泰"）、李虹女士、刘双 全先生、魏永梅女士计划自2025年7月11日起的6个月内，通过集中竞价交易、大 宗交易等法律法规允许的方式增持公司股票，计划增持公司股份不低于 14,339,000股，增持所需资金为自有或自筹资金。 2、风险提示：本次增持计划可能因证券市场情况发生变化、政策因素或因 增持股份所需资金未能及时到位而导致延迟实施或无法实施。如出现上述风险情 形，公司将及时履行信息披露义务。敬请广大投资者注意投资风险。 公司于2025年7月9日收到股东凯诚君泰及其一致行动人李虹女士、 ...

上海凯利泰医疗科技股份有限公司 简式权益变动报告书 上市公司名称：上海凯利泰医疗科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：ST 凯利 股票代码：300326 信息披露义务人 1：上海凯诚君泰投资有限公司 住所：上海市青浦区 信息披露义务人 2：李虹 住所：北京市海淀区 信息披露义务人 3：刘双全 住所：北京市朝阳区 信息披露义务人 4：魏永梅 住所：北京市朝阳区 股权变动性质：股份增加、持股比例达 5% | 第一节 | 释义 4 | | --- | --- | | 第二节 | 信息披露义务人介绍 5 | | 第三节 | 本次权益变动目的 8 | | 第四节 | 权益变动方式 9 | | 第五节 | 前六个月买卖上市公司股份的情况 11 | | 第六节 | 其他重大事项 12 | | 第七节 | 备查文件 13 | 签署日期：二○二五年七月 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》、《上市公司收购管理 办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动 报告书》及相关的法律、法规编写本权益变动报告书； 二、信息披露义务人签署本权益变动报告书已获得 ...

证券代码：300326 证券简称：ST 凯利 公告编号：2025-063 上海凯利泰医疗科技股份有限公司 关于股东持股比例达到5%的权益变动提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示： 2、本次权益变动后，上海凯诚君泰投资有限公司（以下简称"凯诚君泰"）、 李虹女士、刘双全先生、魏永梅女士（以下合称"信息披露义务人"）合计持有 公司股份35,851,406股，占公司总股本的比例增加至5.00%。 3、本次权益变动不会导致公司控制权及公司第一大股东发生变更，不会对 公司经营活动产生影响。 2025年7月7日，上海凯利泰医疗科技股份有限公司（以下简称"公司"）， 收到股东凯城君泰、李虹女士、刘双全先生、魏永梅女士出具的《上海凯利泰医 疗科技股份有限公司简式权益变动报告书》（以下简称"《简式权益变动报告书》"）， 其中提及：信息披露义务人在2025年4月1日至2025年7月7日期间，通过二级市场 集中竞价方式累计增持本公司股份 10,719,200股，占公司总股本的1.4949%。本 次权益变动完成后，信息披露义务人共持有公司35,85 ...

【导读】涌金投资拟3.71亿元要约收购ST凯利10%股份 中国基金报记者 林雪 医疗器械公司ST凯利被"涌金系"再度增持，要约收购。 7月7日晚间，ST凯利公告称，涌金投资控股有限公司（以下简称涌金投资）拟以5.18元/股要约收购公司7170万股股份，占公司总股本的10%，所需最高 资金总额约为3.71亿元；此后，涌金投资将最多持有公司16.99%的股份，可能成为控股股东。 该股近年来经营业绩表现不太好，今年因2024年年报被出具了保留意见的审计报告等，被ST。ST凯利今年整体跌幅超21%。 涌金投资3.71亿元收购10%股份 可能成为ST凯利控股股东 ST凯利7月7日晚间发布的公告显示，公司近日收到涌金投资发来的《上海凯利泰医疗科技股份有限公司要约收购报告书摘要》。此次要约价格为5.18元/ 股，要约收购股份数量为7170.13万股，占上市公司总股本的10%，所需最高资金总额约为3.71亿元。 | 股份种类 | 要约价格 | 要约收购股份数量 | 占已发行股份的比例 | | --- | --- | --- | --- | | | (元/股) | (股) | | | 无限售条件流通股 | 5.18 | 71, ...

Group 1 - The core point of the article is that Yongjin Investment intends to make a tender offer to acquire 10% of ST Kelly's total share capital at a price of 5.18 yuan per share [1] - The total number of shares targeted for acquisition is 71.7 million [1] - The tender offer is not aimed at terminating the company's listing status [1] Group 2 - Yongjin Investment will use its own funds to finance the tender offer [1] - A performance guarantee amounting to at least 20% of the total required funds for the tender offer will be deposited into a designated account within two trading days following the announcement of the tender offer [1]